ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Valve Disease

June 30, 2020
Researchers from the UK reported a novel polymeric heart valve, PoliValve, which is made entirely from styrenic block copolymers. 
February 26, 2020
Five year results of the PARTNER II trial demonstrated no difference in the risk of stroke or death comparing TAVR to surgical aortic valve replacement among intermediate surgical risk patients.  
February 24, 2020
In 2014, Edwards Lifescience launched an ambitious philanthropic initiative called Every Heartbeat Matters (EHM) with the goal of impacting the global burden of heart valve disease through the education, screening and treatment of 1 million underserved people by 2020.
January 8, 2020
A medium size RCT with encouraging surgical outcomes in the era of TAVI expansion.....
November 22, 2019
Puzzling subgroup from the GALILEO trial, which appears in the same issue of the periodical as an article that discredits the use of rivaroxaban as thromboprevention strategy :
November 7, 2019
Data from the PARTNER trials were assessed regarding post-procedural prosthetic valve endocarditis (PVE) after transcatheter aortic valve replacement and surgical aortic valve replacement. The timing and rates of PVE were similar between the groups, and they had a similar high mortality.
November 6, 2019
Gudala and associates performed a literature review of 108 patients who sustained left ventricular rupture following mitral valve replacement. The incidence in pooled data was 0.72%. The authors expounded on the mechanisms, classification, repair techniques, and treatment outcomes of this dreadful complication.
November 2, 2019
Participation in a post-discharge rehabilitation program after valve surgery was associated with a 34% relative decrease in hospitalization during the first year and a 61% relative decrease in mortality at one year.
October 12, 2019
Excellent document from the EACTS, STS, and AATS emphasizing the importance of standardization of prosthetic heart valve labeling.
October 10, 2019
Reporting of postmarket outcomes for the Sapien 3 and Mitraclip devices frequently misclassified patient deaths as device malfunction or other outcomes. Misclassification for Sapien 3 involved 17.5% of patient deaths, and involved 24.7% of patient deaths for Mitraclip.

Pages